Autres langues Bolt Biotherapeutics, Inc.

Actions

BOLT

US0977021049

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 20/05/2024			Varia. 5j.	Varia. 1 janv.
0,79 ^USD	-0,37 %		-40,60 %	-29,46 %

15/05	Les plus fortes baisses de la mi-journée	MT
15/05	BOLT BIOTHERAPEUTICS, INC. : Leerink Partners passe à neutre sur le dossier	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLT	17/05
Top Midday Decliners	15/05
Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50%	15/05
Top Premarket Decliners	15/05
Investors Await Key Inflation Data for April as US Futures Remain Flat in Wednesday's Premarket	15/05
Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team	14/05
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update	21/03
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference	27/02
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®	05/12
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating Bdc-1001 in Patients with Her2-Positive Breast Cancer Previously Treated with Enhertu	05/12
Bolt Biotherapeutics Insider Sold Shares Worth $128,993, According to a Recent SEC Filing	01/12
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	09/11
Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference	07/11
Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress	23/10/23
Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress	23/10/23
Bolt Biotherapeutics, Inc. Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress	23/10/23
Bolt Biotherapeutics : Boltbody™ISAC Platform	20/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Bolt Biotherapeutics, Inc.

Actions

BOLT

US0977021049

Autres langues

Filtres